Having trouble viewing this e-mail? Click here

ModernMedicine/Physician's Focus
Botox for Urologic Conditions

Although botulinum neurotoxins are currently being evaluated for urologic disorders and are not yet FDA-approved, results from a 2005 study show that Botulinum toxin Type A can significantly decrease signs and symptoms of urinary incontinence. ModernMedicine provides several thought-provoking articles on this topic.

Covered in the Physician�s Focus:

  • Research points to expanding role of botulinum toxin in several urologic indications
  • BPH/LUTS treatment choices expand, evolve
  • Botulinum toxin shows efficacy in detrusor overactivity
  • Black box warnings added to botulinum toxin labels; names revised

You are subscribed to ModernMedicine. To unsubscribe, click here

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.